Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Embracer Group in connection with a EUR 900 million bridge facility agreement entered into with JP Morgan, BNP Paribas, SEB, Société Générale and Swedbank.
Mandate

Vinge has advised Embracer Group in connection with a EUR 900 million bridge facility agreement entered into with JP Morgan, BNP Paribas, SEB, Société Générale and Swedbank

April 22, 2024 Banking and Finance

Vinge has advised Embracer Group AB (publ) (“Embracer”) and its subsidiary group Asmodee in connection with the entry into of a EUR 900,000,000 financing agreement with JP Morgan, BNP Paribas, SEB, Société Générale and Swedbank and concurrent prepayment of existing Embracer indebtedness.

Embracer is a global group of entrepreneurial businesses in the gaming and entertainment industry, in which Asmodee is a French developer of board games, card games and role-playing games. The financing is an important step in Embracer’s debt refinancing and restructuring program and will be used to refinance Embracer’s existing SEK 8 billion loan with maturity in February 2025, and to reduce the revolving credit facilities by SEK 1 billion to SEK 8 billion.

Vinge’s team consisted of Louise Brorsson Salomon, Albert Wållgren, Felix Möller, Ida Redander and Josef Groow.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025